The alarmin Interleukin-33 modulates platelet proteome, function and biogenesis
Platelets, traditionally recognized for their involvement in hemostasis and wound healing, also play a central role in immune regulation and inflammation. Their function and production adapt in response to inflammatory cues such as cytokines and danger-associated molecular patterns. Interleukin-33 (IL-33), an alarmin released during tissue damage, particularly in lung inflammation, has been implicated in influencing platelet biology, though its exact effects remain poorly understood. To clarify IL-33's role, we examined its impact on platelet production, proteome, adhesion, secretion, and aggregation using platelets from IL-33-deficient (IL-33KO) mice and IL-33 stimulation in vivo. Our results reveal that while platelets themselves do not express IL-33, platelets isolated from IL-33KO mice display altered proteomic signatures and reduced adhesion to fibrinogen, podoplanin, and laminin, alongside impaired thrombus formation under shear stress. IL-33 administration in vivo led to proteomic remodeling characterized by increased expression of inflammatory proteins, as well as changes in platelet morphology, including increased size, typically associated with de novo production. Using lung intravital microscopy, we visualized platelet fragmentation within the lung vasculature in real time, and observed enhanced fragmentation following IL-33 stimulation. Interestingly, ST2, the receptor for IL-33, is expressed in subsets of mouse and human megakaryocytes and hematopoietic progenitors, particularly those involved in a non-canonical pathway of thrombopoiesis that enables the rapid replenishment of platelets during inflammation, infection, and aging. Together, these findings identify IL-33 as a pivotal regulator of platelet function and production, linking inflammatory signaling to the dynamic regulation of thrombopoiesis.
Authors
- Lucie Gelon
- E. A. G. Vidal
- Stéphane Roga (ORCID: https://orcid.org/0000-0003-3840-3887)
- Sonia Séverin (ORCID: https://orcid.org/0000-0002-1566-2619)
- Emma Lefrancais
- Anne Gonzalez-de-Peredo
- Jean-Philippe Girard
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Institut de Pharmacologie et de Biologie Structurale (FR)
- Institut des Maladies Métaboliques et Cardiovasculaires (FR)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1182/bloodadvances.2025018363
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00